Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Annals of Hematology
|
March 1, 1993
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results
A Ganser, G Heil, K Kolbe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1995
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group
D Peest, H Deicher, R Coldewey, et al.
Seminars in Oncology
|
December 1, 1993
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia
R Haas, A D Ho, F Del Valle, et al.
Klinische Wochenschrift
|
November 2, 1987
Acute myelofibrosis in megakaryoblastic leukemia with translocation between chromosomes 8 and 14
M Winkelmann, C Aul, R E Scharf, et al.
British Journal of Haematology
|
December 31, 1997
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone
R F Schlenk, H Döhner, M Pförsich, et al.
Onkologie
|
December 1, 1990
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group
D Peest, H Deicher, R Coldewey, et al.
Annals of Hematology
|
April 22, 1999
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
W K Hofmann, A Ganser, G Seipelt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 7, 2002
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial
E Heidemann, H Stoeger, R Souchon, et al.
Annals of Hematology
|
February 9, 2000
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
A Ganser, G Heil, G Seipelt, et al.
Oncology
|
March 1, 1997
Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer
C H Köhne, H Wilke, W Hiddemann, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Annals of Hematology
|
March 1, 1993
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results
A Ganser, G Heil, K Kolbe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1995
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group
D Peest, H Deicher, R Coldewey, et al.
Seminars in Oncology
|
December 1, 1993
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia
R Haas, A D Ho, F Del Valle, et al.
Klinische Wochenschrift
|
November 2, 1987
Acute myelofibrosis in megakaryoblastic leukemia with translocation between chromosomes 8 and 14
M Winkelmann, C Aul, R E Scharf, et al.
British Journal of Haematology
|
December 31, 1997
Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone
R F Schlenk, H Döhner, M Pförsich, et al.
Onkologie
|
December 1, 1990
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group
D Peest, H Deicher, R Coldewey, et al.
Annals of Hematology
|
April 22, 1999
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
W K Hofmann, A Ganser, G Seipelt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 7, 2002
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial
E Heidemann, H Stoeger, R Souchon, et al.
Annals of Hematology
|
February 9, 2000
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
A Ganser, G Heil, G Seipelt, et al.
Oncology
|
March 1, 1997
Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer
C H Köhne, H Wilke, W Hiddemann, et al.
Page
of 5